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A Tale of 2 Biologies
Stem Cell Patch:
Myocardial Interactions Are
Critical for Myocardial Regeneration*
Marc S. Penn, MD, PHD,†‡
Horst A. von Recum, PHD§
Akron, Rootstown, and Cleveland, Ohio
The field of cardiovascular regenerative therapy has rapidly
moved from the laboratory to the clinic. Several phase I and
II clinical trials have been conducted using adult stem cell
therapy (1,2), and the field is now entering an important
stage with the announcement of the first pivotal phase III
trial powered to achieve a mortality endpoint in patients
with acute ST-segment elevation myocardial infarction by a
European consortium (BAMI [The Effect of Intracoronary
Reinfusion of Bone Marrow Derived Mononuclear Cells
(BM-MNC) on All-Cause Mortality in Acute Myocardial
Infarction] trial). Although the original hope for adult stem
cell therapy was the regeneration of lost cardiac myocytes
(3), there is little evidence to date that adult stem cells lead
to significant regeneration of cardiac myocytes when deliv-
ered in the setting of acute myocardial infarction (AMI) or
ischemic cardiomyopathy. That said, adult stem cell therapy
has consistently shown clinical benefit in AMI and chronic
heart failure (4), and its investigation at the bench and in the
clinic continues at a rapid pace.
See page 2118
Several years ago we proposed that cardiovascular regen-
erative medicine will develop over 3 stages (5). Stage I was
the cell stage in which specific populations or mixed
populations of adult stem cells would be delivered to
patients with AMI or chronic heart failure. Stage II would
focus on the delivery of the paracrine factors that are
released by and the effectors of adult stem cells. This stage
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contents of this paper to disclose.would focus on gene transfer, cell-based gene transfer
protein therapy, or small molecule delivery. Stage III would
achieve true myocardial regeneration in which embryonic
stem cells or induced pluripotent stem cells (iPSCs) would
be used to introduce new cardiac myocytes to the injured
myocardium. Importantly, this stage will require tissue
engineering to learn how to generate and introduce ex
vivo–generated contractile units to the injured myocardium.
Stages I and II are under investigation in both the basic
and clinical laboratories. Our group has been privileged in
leading the pre-clinical and clinical development of the
multipotent adult progenitor cell for the prevention of
cardiac dysfunction in AMI (6) (Clinicaltrials.gov;
NCT00677222). We have similarly pioneered the science
and clinical translation of the stromal cell–derived factor 1
for the prevention and treatment of cardiac dysfunction
(7,8) (Clinicaltrials.gov; NCT01082094). Dozens of other
groups throughout the world have similarly studied and
translated adult stem cells for the prevention and treatment
of cardiac dysfunction (9,10).
In this issue of the Journal, Dai et al. (11) demonstrate the
complexity of stage III of cardiac regenerative medicine—
true myocardial regeneration. In their study, they developed
a patch that they term Tri-P for tricell patch because it
contains cardiac myocytes derived from iPSCs, endothelial
cells, and mouse embryonic fibroblasts. The authors ele-
gantly demonstrated the need for each of the cell types and
that the combination of just endothelial cells and iPSC-
derived cardiac myocytes did not result in a homogeneous
patch. These findings demonstrate that the inclusion of
critical cell types without an organizing or supportive cell
type that releases critical paracrine factors will be insufficient
for patch generation and further confirm observations from
multiple research groups that stromal cells (e.g., fibroblasts)
are critical for organized neovascularization (12). Their
studies also demonstrate that the draping of the patch over
the injured myocardium 7 days after myocardial infarction
led to significant improvements in cardiac function and
remodeling 4 weeks later (11).
Although these findings are of interest and important, the
authors went on to investigate how myocardial fibrosis
affects the engraftment of and functional response to the
patch. Ultimately one of the significant challenges of true
myocardial regeneration is how best to introduce the car-
diogenic patch or contractile unit to the injured myocar-
dium, particularly because cell orientation and cell-cell
junctions in the Tri-P are initially random and obtaining an
aligned patch of cells suitable for transplantation is chal-
lenging (13). In this study, the authors compared the effects
of the Tri-P in wild-type mice and AC6 transgenic mice.
The AC6 (adenylyl cyclase 6) transgenic develop less
fibrosis and, in particular, less type I collagen than wild-type
mice. The authors convincingly demonstrate across a num-
ber of parameters that the decrease in fibrosis correlates with
improved engraftment of the Tri-P, and functional response
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Other studies have demonstrated an important inverse
relationship between myocardial fibrosis and stem cell–
based repair of the heart. Xiang et al. (14,15) demonstrated
that inhibition of myocardial fibrosis through down-
regulation of plasminogen activator inhibitor 1 activity led to
greater stem cell recruitment to the heart, improved vascular
density, and myocardial function. Of course there are limits
because the complete inhibition of plasminogen activator
inhibitor 1 uniformly leads to myocardial rupture (16).
Based on this study, one can speculate that the fibrosis
that is present in the chronically remodeled myocardium of
patients with chronic heart failure and ischemic cardiomy-
opathy could limit the efficacy of the contractile units in
myocardial patches. If future studies validate this specula-
tion, then the field will need to develop novel delivery
strategies for the integration of myocardial patches. The
recent negative results of the efficacy of scar resection in the
STITCH (Simplified Treatment Intervention to Control
Hypertension) trial (17) may need to be revisited if we find
that stem cell–generated myocardial patches need to bridge
viable border zones. Conversely, one can envision a role for
biologics that can modify the fibrotic area to enhance
engraftment and growth of the myocardial patch. Regard-
less of the approach, it seems likely that true myocardial
regeneration with ex vivo–generated myocardial patches
will be the purview of the cardiothoracic surgeon in the
foreseeable future.
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